| Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
| Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'MRA' found in 2 terms [] and 57 definitions []
| previous 31 - 35 (of 59) nextResult Pages : [1] [2 3 4 5 6 7 8 9 10 11 12] | | | | Searchterm 'MRA' was also found in the following services: | | | | |
| | |
| |
|
Short name: (Gd-DTPA)-17, 24 cascade polymer, generic name: Gadomer-17, 24, central moiety: Gd2+, relaxivity: r1=11.9, B0=1.0 T, r2=16.5, Dose: 0.05 mmol/kg
An intravascular macromolecular MRI contrast agent with positive enhancement under development ( Bayer Schering Pharma AG) for MR angiography and tumor differentiation. The synthetic dendrimer with large molecular weight (17kD - limits agent to vascular space) is linked to Gadolinium.
The renal excretion is slowed to intermediate molecular size. In MRA a longer lasting venous and arterial enhancement was seen with Gadomer-17 due to the particular pharmacokinetics of this agent.
See also Tumor Specific Agents, and Intravascular Contrast Agents. | | | | • View the NEWS results for 'Gadomer 17' (1).
| | | | Further Reading: | News & More:
|
|
| |
| | | | | |
| |
|
Short name: PLLGd-DTPA, generic name: (Gd-DTPA)n-polylysine, chemical compound: Gd-DTPA poly(L-lysine-Gd-diethylenetriamine-N,N,N',N'',N''-pentaacetic acid), central moiety: Gd2+, relaxivity: r1=13.1, B0=0.23T
A polymeric MRI contrast agent under development (preclin., Bayer Schering Pharma AG, Berlin, Germany) with advantages in both MRA and in the differential diagnosis of tumors, particularly in perfusion studies of the myocardium and potential in MR lung perfusion.
Dozens of the relatively small molecule Gd-DTPA is bound covalently to polylysine, a large molecular weight backbone. The stable, highly water-soluble agent does not diffuse through the endothelium of the vascular system; it is subject to renal elimination. | | | | • View the DATABASE results for 'Gd-DTPA-Polylysine' (2).
| | | | |
| | | | | |
| |
|
| | | | | | | | | • View the NEWS results for 'Heart MRI' (18).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
| | | Searchterm 'MRA' was also found in the following services: | | | | |
| | |
| |
|
The principal advantage of MRI at high field is the increase in signal to noise ratio. This can be used to improve anatomic and/or temporal resolution and reduce scan time while preserving image quality. MRI devices for whole body imaging for human use are available up to 3 tesla (3T). Functional MRI ( fMRI) and MR spectroscopy ( MRS) benefit significantly. In addition, 3T machines have a great utility in applications such as TOF MRA and DTI. Higher field strengths are used for imaging of small parts of the body or scientific animal experiments. Higher contrast may permit reduction of gadolinium doses and, in some cases, earlier detection of disease.
Using high field MRI//MRS, the RF-wavelength and the dimension of the human body complicating the development of MR coils. The absorption of RF power causes heating of the tissue. The energy deposited in the patient's tissues is fourfold higher at 3T than at 1.5T. The specific absorption rate (SAR) induced temperature changes of the human body are the most important safety issue of high field MRI//MRS.
Susceptibility and chemical shift dispersion increase like T1, therefore high field MRI occasionally exhibits imaging artifacts. Most are obvious and easily recognized but some are subtle and mimic diseases. A thorough understanding of these artifacts is important to avoid potential pitfalls. Some imaging techniques or procedures can be utilized to remove or identify artifacts. See also Diffusion Tensor Imaging.
See also the related poll result: ' In 2010 your scanner will probably work with a field strength of' | | | | | | • View the DATABASE results for 'High Field MRI' (16).
| | | • View the NEWS results for 'High Field MRI' (9).
| | | | Further Reading: | Basics:
|
|
News & More:
| |
| |
| | | | | | | | | |
| | | |
|
| |
| Look Ups |
| |